# Biotech Daily

Thursday July 30, 2026

*Daily news on ASX-listed biotechnology companies*

*** ASX, BIOTECH DOWN: LUMOS UP 10%; ARTRYA DOWN 16%**

*** MESOBLAST RECEIPTS UP 15.5-FOLD TO $127m**

*** IMMUTEP $29m RECEIPTS - DR REDDY'S EFTI LICENCE**

*** EPSILON H1 RECEIPTS UP 102% TO $7m**

*** CANN RECEIPTS DOWN 23% TO $10m**

*** CLEVER CULTURE RECEIPTS UP 5% TO $4.9m**

*** AUDEARA RECEIPTS DOWN 14% TO $4m**

*** ONCOSIL RECEIPTS UP 179% TO $2m**

*** EBR: '117 COMMERCIAL WISE IMPLANTS TO-DATE'**

*** QUEENSLAND UNI NON-INVASIVE SENSOR FOR ROBOTICS**

*** AUSCELERATE: 'TTRA PROGRAM LED TO $220m INVESTMENT'**

*** LUMOS: ALPHA MEDICAL ROMANIA FEBRIDX DISTRIBUTOR**

*** INVICTUS ALLOWED US TRANSMUCOSAL TOCOTRIENOL PATENT**

*** NIV DAGAN, 10 BOLIVANOS, FREEDOM TRADER TAKE 15% OF NEXALIS**

MARKET REPORT

The Australian stock market fell 0.78 percent on Thursday July 30, 2026, with the ASX200 down 70.9 points to 8,967.7 points. Ten of the Biotech Daily Top 40 companies were up, 23 fell, six traded unchanged and one was untraded.

Lumos was the best, up one cent or 10 percent to 11 cents, with 1.5 million shares traded. Actinogen and Botanix were up more than five percent; Dimerix climbed 4.2 percent; Alcidion and Neuren rose more than two percent; Prescient and Starpharma were up more than one percent; with Clarity and Resmed up by less than one percent.

Artrya led the falls, down 77 cents or 16.1 percent to $4.00, with3.45 million shares traded. Resonance lost 5.0 percent; Polynovo fell 4.0 percent; Amplia, Avita, Clinuvel, Imugene, Medical Developments, Micro-X, Nova Eye, Paradigm, Proteomics, Racura and Telix were down three percent or more; Aroa, Immutep, Imricor, Pro Medicus and Saluda shed two percent or more; 4D Medical, Cyclopharm, Emvision and Orthocell were down more than one percent; with Cochlear, CSL and Nanosonics down by less than one percent.

MESOBLAST
Mesoblast says customers receipt for the year to June 30, 2026 were up 15.5-fold to $US88,447,000 ($A127,048,000), compared to the previous corresponding period.
Mesoblast said customer receipts for the three months to June 30, 2026 from sales of its Ryoncil, or remestemcel-L, for graft versus host disease and royalties on Temcell rose 21.9-fold to $US25,839,000, compared to the previous corresponding period.
Last year, the company said it had US Food and Drug Administration approval for Ryoncil for children with graft versus host disease (BD: Dec 19, 2024).
Today, Mesoblast said net revenue from sales of Ryoncil for the first full-year post-FDA approval was $US115 million.
Mesoblast chief executive Prof Silviu Itescu said the company was “very pleased with the continued momentum in uptake of Ryoncil in children with life-threatening steroid-refractory acute [graft versus host disease] across major US paediatric centres, positioning the treatment well for use next in adults with this life-threatening disease”.
“We will continue to build on the strong first full year of Ryoncil revenue to ensure our judicious use of capital facilitates achievement of key inflexion points for our blockbuster products, including potential FDA approvals,” Prof Itescu said.
The company said it had a $US9,254,000 three-month cash burn, with cash and equivalents of $US102,914,000 at June 30, compared to $US161,551,000 the prior year.
Mesoblast was unchanged at $2.04 with 4.2 million shares traded.

IMMUTEP
Immutep says it has receipts from customers for the year to June 30, 2026 of $28,880,000, mostly related to its licencing of efti to Dr Reddy’s Laboratories.
Last year, Immutep said the Hyderabad, India-based Dr Reddy’s licenced its eftilagimod alfa, or efti, in all countries outside North America, Europe, Japan and Greater China for up-to $558.6 million, with $US20 million ($A30.2 million) up-front (BD: Dec 9, 2025).
Today, the company said it had a cash burn of $38,891,000 for the three months, with cash and cash equivalents of $63,673,000 at June 30, 2026 compared to $67,408,000 at June 30, 2025, leaving it with 1.64 quarters of cash.
Immutep said that net operating cash outflow was not expected to continue at the same level, with a one-off $14.1 million repayment to Dr Reddy’s made during the period triggered by the discontinuation of an efti trial and costs to reduce following the wind-down of another efti trial.
Earlier this year, Immutep fell as much as 92.9 percent on news that the ‘Tacti-004’ phase III trial of ‘efti’ with chemotherapy for first line non-small cell lung cancer had been discontinued (BD: Mar 13, 2026).
Immutep fell 0.1 cents or 2.1 percent to 4.6 cents with 11.7 million shares traded.

EPSILON HEALTHCARE
Epsilon says receipts from customers for the six months to June 30, 2026 were up 102.05 percent to $6,799,000, compared to the previous corresponding period.
Epsilon said record customer receipts for the three months to June 30, 2026 from its marijuana contract development and manufacturing services, clinics and pharmacy businesses rose 71.7 percent to $3,659,000, compared to the prior period.
The company said it was $1,068,000 cash flow positive for the three months, with cash and equivalents of $1,469,000 at June 30, 2026 compared to $923,000 at June 30, 2025.
Epsilon was untraded at 2.3 cents.

## CANN GROUP

Cann says receipts from customers for the year to June 30, 2026 fell 23.2 percent to $10,031,000, compared to the previous corresponding period.
Cann said that customer receipts from sales of its marijuana products were down 10.6 percent to $2,553,000 for the three months to June 30, 2026, compared to the prior corresponding period.
The company said that payments to suppliers and staff were down about 22 percent to $2.57 million on the prior three months (to March 31, 2026) as it continued “to be vigilant with its expense management”.
Cann said it was $237,000 cash flow positive for the three months.
The company said that it had cash and cash equivalents of $487,000 as well as $15,356,000 in unused financing facilities at June 30, 2026, compared to $10,000 in cash at June 30, 2025.
Cann was unchanged at 0.3 cents with 19 million shares traded.

## CLEVER CULTURE SYSTEMS (FORMERLY LBT INNOVATIONS)

Clever Culture says receipts from customers for the year to June 30, 2026 rose 5.3 percent to $4,897,000, compared to the previous corresponding period.
Clever Culture said that customer receipts from sales of its automated plate assessment system (Apas) Independence instrument and software for environmental monitoring for the three months to June 30, 2026 fell 37.95 percent to $551,000, compared to the prior corresponding period.
Clever Culture Systems said that it had a cash burn of $1,679,000 for the three months to June 30, 2026.
The company said that it had cash and equivalents of $1,687,000 at June 30, 2026 compared to $1,265,000 at June 30, 2025, leaving it with 1.08 quarters of cash.
Clever Culture said that it expected to improve its cash operating inflows “over the near term” with $3.4 million expected within six months from debtors, as well as its anticipated Federal Research and Development Tax Incentive and committed cash inflows from customers.
Clever Culture fell 0.1 cents or 5.9 percent to 1.6 cents.

## AUDEARA

Audeara says receipts from customers for the year to June 30, 2026 fell 14.0 percent to $4,212,000, compared to the previous corresponding period.
Audeara said it had full-year unaudited revenue of $4.44 million, up 17.3 percent from $3.786 in the prior year from sales of its hearing health products.
The company said customer receipts for the three months to June 30, 2026 were down 25.9 percent to $709,000, compared to the prior corresponding period.
Audeara said it had a cash burn of $795,000 for the three months, with cash and cash equivalents of $740,000 at June 30, 2026 compared to $1,422,000 at June 30, 2025, leaving it with 0.93 quarters cash.
The company said it did not expect to maintain its current level of cash outflows, was progressing “revenue-generating initiatives” and implementing cost management strategies to improve future operating cash flows.
Audeara was untraded at three cents.

## ONCOSIL MEDICAL

Oncosil says receipts from customers for the year to June 30, 2026 were up 179.0 percent to $2,115,000, compared to the previous corresponding period.
Oncosil said sales of its phosphorous-32 pancreatic cancer therapy device for the three months rose 187.5 percent to $391,000, compared to the prior corresponding period.
The company said it delivered “another year of strong commercial growth, with unit sales increasing 53 percent and revenue growing 44 percent in 2025-’26 compared with 2024-’25”, reflecting increased adoption of its device across Europe and supported by its expanding clinical evidence and regulatory achievements.
In May, Oncosil said the Australian TGA had approved the device (BD: May 20, 2026).
Today, the company said it had a $2,582,000 three-month cash burnf, with cash and cash equivalents of $6,476,000 at June 30, 2026 compared to $5,121,000 at June 30, 2025.
Oncosil was unchanged at $1.11.

## EBR SYSTEMS

EBR says its Wise leadless cardiac re-synchronization therapy has been implanted in a total of 117 commercial patients, with 52 total purchasing contracts signed.
Last year, EBR said the US Food and Drug Administration approved Wise cardiac re-synchronization therapy (CRT) for left ventricular pacing and later said it had US Centers for Medicare & Medicaid Services (CMS) approval for the “new technology add-on payment”, confirming “the maximum reimbursement rate of up-to $US41,145 ($A63,696) based on an average Wise selling price of $US63,300” (BD: Apr 14, Aug 5, 2025).
Biotech Daily calculates that based on the average Wise selling price, the 117 commercial implants of the device completed to date amount to $US7,406,100.
EBR said 90 physicians at 30 sites were trained to implant the Wise system, with 26 trained during the three months to June 30, 2026.
The company said it was “moderating the pace of new site activations and increasing its focus on deeper utilization within existing activated accounts, supporting repeat procedural experience, internal field capability and more consistent case scheduling”.
EBR chief executive officer John McCutcheon said the three months were “another successful quarter of commercial execution for EBR, with continued progress across Wise implant activity, purchasing contracts and physician training”.
EBR was unchanged at 27.5 cents with 3.1 million shares traded.

## THE UNIVERSITY OF QUEENSLAND

The University of Queensland says it has developed a non-invasive sensor that measures muscle forces for wearable robotic mobility devices.
The University said the ultra-wideband radar sensors measured electro-magnetic changes in muscles as they contracted, collecting data “that’s never been done before”; and the sensors had “the potential for several applications, including robotic or prosthetic devices”.
The University of Queensland said the research, titled ‘Ultra-wideband radar to measure in vivo muscle forces’ was published in Science Robotics, with the full article at: https://www.science.org/doi/10.1126/scirobotics.aed5865.
The University said “ultra-wideband radar antennas, which sit on top of the skin, send electromagnetic pulses into the muscles and record how the transmitted and reflected signals change as the muscle contracts”.
The University of Queensland said the goal was to “have the sensors able to measure forces in real time, allowing them to be used as an input for assistive devices”.

## [AUSCELERATE (FORMERLY MTP CONNECT)]

Auscelerate says it has a report shows its inaugural Targeted Translation Research Accelerator (TTRA) program led to the investment of $220 million.
Auscelerate said the report, titled 'Vital Signs: Boosting Australian Innovation in Heart and Diabetes Health' showed that the six-year program led to the opening of 47 clinical trials involving 5,000 people and "supercharged the translation of 80 new heart and diabetes products and solutions towards clinical and community impact".
The organization said the program was supported by the Federal Government's Medical Research Future Fund and "de-risked innovations for private investment, increased funding into Australia's life sciences sector and made a real-world impact".
Auscelerate said the program led to the opening of the Australian Centre for Accelerating Diabetes Innovations (ACADI) at the University of Melbourne and the Australian Stroke and Heart Research Accelerator (ASHRA).
The organization said the report was available at: https://bit.ly/4wxo6Fx.
Auscelerate chief executive officer Stuart Dignam said innovations supported included "new therapies, treatment strategies and strengths-based models of care for kidney disease, peripheral artery disease, athero-sclerosis and stroke, improved glucose control, coronary artery disease, heart failure, mental health and First Nations health and wellbeing".
"Achievements include development of an oral insulin drug delivery platform, a controller for the Bivacor total artificial heart, antithrombotic therapies for better stroke treatment, technology to detect unstable coronary plaques, as well as the world's first national helpline providing mental health support via telehealth directly to adults with diabetes and cardiovascular disease," Mr Dignam said.

## LUMOS DIAGNOSTICS

Lumos says Bucharest's Alpha Medical will distribute and sell its Febridx blood test for differentiating bacterial from non-bacterial infections in Romania.
Lumos said Alpha Medical supplied primary care, urgent care and hospitals with medical equipment and consumables and provided product support and servicing in Romania.
The company said Alpha would oversee sales, distribution and inventory management of Febridx in Romania, supported by its logistics network and customer relationships.
Lumos said Alpha Medical had placed an initial order to support the availability of Febridx, and it continued "to build a broad European distribution network for Febridx" with agreements in the UK, Spain, Portugal, the Netherlands, Lithuania, Estonia and Latvia.
The company did not disclose the commercial terms of the agreement.
Lumos was up one cent or 10 percent to 11 cents with 1.5 million shares traded.

## INVICTUS THERAPEUTICS

Invictus says the US Patent and Trademarks Office has allowed a patent protecting its transmucosal tocotrienol for post-exercise and delayed onset muscle soreness.
Invictus said the patent, titled 'Transmucosal Delivery of Tocotrienol' would protect its intellectual property until December 4, 2040 and related to an improved method for the manufacture of formulations of tocotrienol for transmucosal administration.
The company said it had protection for its first family of patents in the US, Canada, Japan, the EU, Australia, New Zealand, Singapore and South Africa, with additional second family patents to be granted pending applications in Japan and the EU.
Invictus is listed on the National Stock Exchange (NSX:VTL) and last traded at two cents.

## NEXALIS THERAPEUTICS (FORMERLY INHALERX)

Niv Dagan, 10 Bolivanos and Freedom Trader say they increased their substantial holding in Nexalis from 10,172,302 shares (11.38%) to 37,466,309 shares (14.81%).

Melbourne's Niv Dagan, 10 Bolivanos and Freedom Trader said that they bought shares between October 6, 2021 and July 13, 2026 at prices ranging from one cent or 10 cents a share.

Nexalis was untraded at 1.1 cents.